

(12)

NEW EUROPEAN PATENT SPECIFICATION

- (45)

Date of publication and mention of the opposition decision:  
13.03.2002 Bulletin 2002/11
- (51)

Int Cl.7: C12N 15/13, C12N 15/63, C12N 15/81, C12N 15/85, C12P 21/00, A61K 39/395
- (45)

Mention of the grant of the patent:  
05.06.1991 Bulletin 1991/23
- (21)

Application number: 84302368.0
- (22)

Date of filing: 06.04.1984

(54) Recombinant immunoglobulin preparations

Rekombinante Immunoglobulin-Präparate

Préparations d'immunoglobuline recombinante

<div><div>(84)</div><div>Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE</div></div> <div><div>(30)</div><div>Priority: 08.04.1983 US 483457</div></div> <div><div>(43)</div><div>Date of publication of application: 14.11.1984 Bulletin 1984/46</div></div> <div><div>(73)</div><div>Proprietors:<ul style="list-style-type: none"><li>GENENTECH, INC. South San Francisco California 94080 (US)</li><li>CITY OF HOPE Duarte California 91010 (US)</li></ul></div></div> <div><div>(72)</div><div>Inventors:<ul style="list-style-type: none"><li>Cabilly, Shmuel Arcadia California 91006 (US)</li><li>Holmes, William Evans Pacifica California 94044 (US)</li><li>Wetzel, Ronald Burnell San Francisco California 94127 (US)</li><li>Heyneker, Herbert Louis Burlingame California 94010 (US)</li><li>Riggs, Arthur Dale La Verne California 91750 (US)</li></ul></div></div> <div><div>(74)</div><div>Representative: Armitage, Ian Michael et al MEWBURN ELLIS York House 23 Kingsway London WC2B 6HP (GB)</div></div>	<div><div>(56)</div><div>References cited:<div>EP-A- 0 057 107EP-A- 0 068 763</div><div>EP-A- 0 073 656EP-A- 0 088 994</div><div>EP-A- 0 102 634EP-A- 0 120 694</div></div><div><ul style="list-style-type: none"><li>Microbiology, 3rd ed., Harper International Ed. (1980), Chapter 17</li><li>Nucl.Acids Res. vol.8, no.9, 1980, pp. 2055-65</li><li>Proc.Natl.Acad.Sci. USA 78 (1981), pp. 4250-24</li><li>Nature 298 (1982), pp. 286-88</li><li>Molekulare Biologie der Zelle VCH Verlagsgesellschaft m.b.H., Weinheim (1986), p. 1075</li><li>TRENDS IN BIOCHEMICAL SCIENCES, vol.6, no.8, August 1981, North-Holland; N. GOUGH "The rearrangements of immunoglobulin genes", pp. 203-205</li><li>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol.77, no.4, April 1980; G. Köhler "Immunoglobulin chain loss in hybridoma lines", pp. 2197-2199</li><li>THE JOURNAL OF IMMUNOLOGY, vol.123, no.2, August 1979, Baltimore, USA; S.L. MORRISON "Sequentially derived mutants of the constant region of the heavy chain of murine immunoglobulins", pp. 793-800</li></ul></div><div><div>Remarks:</div><div>The file contains technical information submitted after the application was filed and not included in this specification</div></div></div>
---	--

EP 0 125 023 B2

**Description**

**[0001]** This invention relates to the field of immunoglobulin production and to modification of naturally occurring immunoglobulin amino acid sequences. Specifically, the invention relates to using recombinant techniques to produce immunoglobulins which have chimeric forms.

A. Immunoglobulins and Antibodies

**[0002]** Antibodies are specific immunoglobulin polypeptides produced by the vertebrate immune system in response to challenge by foreign proteins, glycoproteins, cells, or other antigenic foreign substances. The sequence of events which permits the organism to overcome invasion by foreign cells or to rid the system of foreign substances is at least partially understood. An important part of this process is the manufacture of antibodies which bind specifically to a particular foreign substance. The binding specificity of such polypeptides to a particular antigen is highly refined, and the multitude of specificities capable of being generated by the individual vertebrate is remarkable in its complexity and variability. Thousands of antigens are capable of eliciting responses, each almost exclusively directed to the particular antigen which elicited it.

**[0003]** Immunoglobulins include both antibodies, as above described, and analogous protein substances which lack antigen specificity. The latter are produced at low levels by the lymph system and in increased levels by myelomas.

A.1 Source and Utility

**[0004]** Two major sources of vertebrate antibodies are presently utilized--generation in situ by the mammalian B lymphocytes and in cell culture by B-cell hybrids. Antibodies are made in situ as a result of the differentiation of immature B lymphocytes into plasma cells, which occurs in response to stimulation by specific antigens. In the undifferentiated B cell, the portions of DNA coding for the various regions on the immunoglobulin chains are separated in the genomic DNA. The sequences are reassembled sequentially prior to transcription. A review of this process has been given by Gough, Trends in Biochem Sci. 6: 203 (1981). The resulting rearranged genome is capable of expression in the mature B lymphocyte to produce the desired antibody. Even when only a single antigen is introduced into the sphere of the immune system for a particular mammal, however, a uniform population of antibodies does not result. The in situ immune response to any particular antigen is defined by the mosaic of responses to the various determinants which are present on the antigen. Each subset of homologous antibody is contributed by a single population of B cells--hence in situ generation of antibodies is "polyclonal".

**[0005]** This limited but inherent heterogeneity has been overcome in numerous particular cases by use of hybridoma technology to create "monoclonal" antibodies (Kohler, et al., Eur. J. Immunol., 6: 511 (1976)). In this process, splenocytes or lymphocytes from a mammal which has been injected with antigen are fused with a tumor cell line, thus producing hybrid cells or "hybridomas" which are both immortal and capable of producing the genetically coded antibody of the B cell. The hybrids thus formed are segregated into single genetic strains by selection, dilution, and regrowth, and each strain thus represents a single genetic line. They therefore produce immunoreactive antibodies against a desired antigen which are assured to be homogenous, and which antibodies, referencing their pure genetic parentage, are called "monoclonal". Hybridoma technology has to this time been focused largely on the fusion of murine lines, but human-human hybridomas (Olsson, L. et al., Proc. Natl. Acad. Sci. (USA), 77: 5429 (1980)); human-murine hybridomas (Schlom, J., et al. (ibid) 77: 6841 (1980)) and several other xenogenic hybrid combinations have been prepared as well. Alternatively, primary, antibody producing, B cells have been immortalized in vitro by transformation with viral DNA.

**[0006]** Polyclonal, or, much more preferably, monoclonal, antibodies have a variety of useful properties similar to those of the present invention. For example, they can be used as specific immunoprecipitating reagents to detect the presence of the antigen which elicited the initial processing of the B cell genome by coupling this antigen-antibody reaction with suitable detection techniques such as labeling with radioisotopes or with enzymes capable of assay (RIA, EMIT, and ELISA). Antibodies are thus the foundation of immuno diagnostic tests for many antigenic substances. In another important use, antibodies can be directly injected into subjects suffering from an attack by a substance or organism containing the antigen in question to combat this attack. This process is currently in its experimental stages, but its potential is clearly seen. Third, whole body diagnosis and treatment is made possible because injected antibodies are directed to specific target disease tissues, and thus can be used either to determine the presence of the disease by carrying with them a suitable label, or to attack the diseased tissue by carrying a suitable drug.

**[0007]** Monoclonal antibodies produced by hybridomas, while theoretically effective as suggested above and clearly preferable to polyclonal antibodies because of their specificity, suffer from certain disadvantages. First, they tend to be contaminated with other proteins and cellular materials of hybridoma, (and, therefore, mammalian) origin. These cells contain additional materials, notably nucleic acid fragments, but protein fragments as well, which are capable of enhancing, causing, or mediating carcinogenic responses. Second, hybridoma lines producing monoclonal antibodies

tend to be unstable and may alter the structure of antibody produced or stop producing antibody altogether (Kohler, G., et al., Proc. Natl. Acad. Sci (USA) 77: 2197 (1980); Morrison, S.L., J. Immunol. 123: 793 (1979)). The cell line genome appears to alter itself in response to stimuli whose nature is not currently known, and this alteration may result in production of incorrect sequences. Third, both hybridoma and B cells inevitably produce certain antibodies in glycosylated form (Melchers, F., Biochemistry, 10: 653 (1971)) which, under some circumstances, may be undesirable. Fourth, production of both monoclonal and polyclonal antibodies is relatively expensive. Fifth, and perhaps most important, production by current techniques (either by hybridoma or by B cell response) does not permit manipulation of the genome so as to produce antibodies with more effective design components than those normally elicited in response to antigens from the mature B cell in situ. The antibodies of the present invention do not suffer from the foregoing drawbacks, and, furthermore, offer the opportunity to provide molecules of superior design.

**[0008]** Even those immunoglobulins which lack the specificity of antibodies are useful, although over a smaller spectrum of potential uses than the antibodies themselves. In presently understood applications, such immunoglobulins are helpful in protein replacement therapy for globulin related anemia. In this context an inability to bind to antigen is in fact helpful, as the therapeutic value of these proteins would be impaired by such functionality. At present, such non-specific antibodies are derivable in quantity only from myeloma cell cultures suitably induced. The present invention offers an alternative, more economical source. It also offers the opportunity of cancelling out specificity by manipulating the four chains of the tetramer separately.

## A.2 General Structure Characteristics

**[0009]** The basic immunoglobulin structural unit in vertebrate systems is now well understood (Edelman, G.M., Ann. N.Y. Acad. Sci., 190: 5 (1971)). The units are composed of two identical light polypeptide chains of molecular weight approximately 23,000 daltons, and two identical heavy chains of molecular weight 53,000-70,000. The four chains are joined by disulfide bonds in a "Y" configuration wherein the light chains bracket the heavy chains starting at the mouth of the Y and continuing through the divergent region as shown in figure 1. The "branch" portion, as there indicated, is designated the Tab region. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, with some subclasses among them, and the nature of this chain, as it has a long constant region, determines the "class" of the antibody as IgG, IgM, IgA, IgD, or IgE. Light chains are classified as either kappa or lambda. Each heavy chain class can be prepared with either kappa or lambda light chain. The light and heavy chains are covalently bonded to each other, and the "tail" portions of the two heavy chains are bonded to each other by covalent disulfide linkages when the immunoglobulins are generated either by hybridomas or by B cells. However, if non-covalent association of the chains can be effected in the correct geometry, the aggregate will still be capable of reaction with antigen, or of utility as a protein supplement as a non-specific immunoglobulin.

**[0010]** The amino acid sequence runs from the N-terminal end at the top of the Y to the C-terminal end at the bottom of each chain. At the N-terminal end is a variable region which is specific for the antigen which elicited it, and is approximately 100 amino acids in length, there being slight variations between light and heavy chain and from antibody to antibody. The variable region is linked in each chain to a constant region which extends the remaining length of the chain. Linkage is seen, at the genomic level, as occurring through a linking sequence known currently as the "J" region in the light chain gene, which encodes about 12 amino acids, and as a combination of "D" region and "J" region in the heavy chain gene, which together encode approximately 25 amino acids.

**[0011]** The remaining portions of the chain are referred to as constant regions and within a particular class do not to vary with the specificity of the antibody (i.e., the antigen eliciting it).

**[0012]** As stated above, there are five known major classes of constant regions which determine the class of the immunoglobulin molecule (IgG, IgM, IgA, IgD, and IgE corresponding  $\gamma$ ,  $\mu$ ,  $\alpha$ ,  $\delta$ , and  $\epsilon$  heavy chain constant regions). The constant region or class determines subsequent effector function of the antibody, including activation of complement (Kabat, E.A., Structural Concepts in Immunology and Immunochemistry, 2nd Ed., p. 413-436, Holt, Rinehart, Winston (1976)), and other cellular responses (Andrews, D.W., et al., Clinical Immunobiology pp 1-18, W.B. Sanders (1980); Kohl, S., et al., Immunology, 48: 187 (1983)); while the variable region determines the antigen with which it will react.

## B. Recombinant DNA Technology

**[0013]** Recombinant DNA technology has reached sufficient sophistication that it includes a repertoire of techniques for cloning and expression of gene sequences. Various DNA sequences can be recombined with some facility, creating new DNA entities capable of producing heterologous protein product in transformed microbes and cell cultures. The general means and methods for the *in vitro* ligation of various blunt ended or "sticky" ended fragments of DNA, for producing expression vectors, and for transforming organisms are now in hand.

**[0014]** DNA recombination of the essential elements (i.e., an origin of replication, one or more phenotypic selection

characteristics, expression control sequence, heterologous gene insert and remainder vector) generally is performed outside the host cell. The resulting recombinant replicable expression vector, or plasmid, is introduced into cells by transformation and large quantities of the recombinant vehicle is obtained by growing the transformant. Where the gene is properly inserted with reference to portions which govern the transcription and translation of the encoded DNA message, the resulting expression vector is useful to produce the polypeptide sequence for which the inserted gene codes, a process referred to as "expression." The resulting product may be obtained by lysis, if necessary, of the host cell and recovery of the product by appropriate purifications from other proteins.

**[0015]** In practice, the use of recombinant DNA technology can express entirely heterologous polypeptide--so-called direct expression--or alternatively may express a heterologous polypeptide fused to a portion of the amino acid sequence of a homologous polypeptide. In the latter cases, the intended bioactive product is sometimes rendered bio-inactive within the fused, homologous heterologous polypeptide until it is cleaved in an extracellular environment.

**[0016]** The art of maintaining cell or tissue cultures as well as microbial systems for studying genetics and cell physiology is well established. Means and methods are available for maintaining permanent cell lines, prepared by successive serial transfers from isolated cells. For use in research, such cell lines are maintained on a solid support in liquid medium, or by growth in suspension containing support nutrients. Scale-up for large preparations seems to pose only mechanical problems.

#### Summary of the Invention

**[0017]** The present invention provides certain chimeric antibodies as set forth in the appended claim.

**[0018]** The invention can be used to prepare antibodies in pure "monoclonal" form. They can be manipulated at the genomic level to produce chimeras. They can also be manipulated at the protein level, since all four chains do not need to be produced by the same cell.

**[0019]** The invention is directed to, immunoglobulins which comprise polypeptides not hitherto found associated with each other in nature. "Fab proteins" may be produced which include only the "Fab" region of an immunoglobulin molecule i.e., the branches of the "Y". These Fab fragments may be chimeric, where for example, the constant and variable sequence patterns may be of different origin. Finally, either the light chain or heavy chain alone, or portions thereof, produced by recombinant techniques may be produced for the invention.

**[0020]** There are described expression vectors or plasmids capable of effecting the production of such immunoglobulins in suitable host cells. It includes the host cells and cell cultures which result from transformation with these vectors. Finally, there are described methods of producing these immunoglobulins and the DNA sequences, plasmids, and transformed cells intermediate to them.

#### Brief Description of the Drawings

##### **[0021]**

Figure 1 is a representation of the general structure of immunoglobulins.

Figure 2 shows the detailed sequence of the cDNA insert of pK17G4 which encodes kappa anti CEA chain.

Figure 3 shows the coding sequence of the fragment shown in Figure 2, along with the corresponding amino acid sequence.

Figure 4 shows the combined detailed sequence of the CDNA inserts of py298 and py11 which encode gamma anti CEA chain.

Figure 5 shows the corresponding amino acid sequence encoded by the fragment in Figure 4.

Figures 6 and 7 Outline the construction of expression vectors for kappa and gamma anti-CEA chains respectively.

Figures 8A, 8B, and 8C show the results of sizing gels run on extracts of *E. coli* expressing the genes for gamma chain, kappa chain, and both kappa and gamma chains respectively.

Figure 9 shows the results of western blots of extracts of cells transformed as those in Figures 8.

Figure 10 shows a standard curve for ELISA assay of anti CEA activity.

Figures 11 and 12 show the construction of a plasmid for expression of the gene encoding a chimeric heavy chain.

Figure 13 shows the construction of a plasmid for expression of the gene encoding the Fab region of heavy chain.

#### Detailed Description

##### A. Definitions

**[0022]** As used herein, "antibodies" refers to tetramers or aggregates thereof which have specific immunoreactive activity, comprising light and heavy chains usually aggregated in the "Y" configuration of Figure 1, with or without



covalent linkage between them; "immunoglobulins" refers to such assemblies whether or not specific immunoreactive activity is a property. "Non-specific Immunoglobulin" ("NSI") means those immunoglobulins which do not possess specificity-i.e., those which are not antibodies.

**[0023]** "Chimeric antibodies" refers to those antibodies wherein one portion of each of the amino acid sequences of heavy and light chains is derived from a particular species, while the remaining segment of the chains is derived from another. Typically, in these chimeric antibodies, the variable region of both light and heavy chains is derived from antibodies from one species of mammals while the constant portions are derived from antibodies from another. One clear advantage to such chimeric forms is that, for example, the variable regions can conveniently be derived from presently known sources using readily available hybridomas or B cells from non human host organisms in combination with constant regions derived from, for example, human cell preparations. While the variable region has the advantage of ease of preparation, and the specificity is not affected by its source, the constant region being human, is less likely to elicit an immune response from a human subject when the antibodies are injected than would the constant region from a non-human source.

**[0024]** "Fab" region refers to those portions of the chains which are roughly equivalent, or analogous, to the sequences which comprise the Y branch portions of the heavy chain and to the light chain in its entirety, and which collectively (in aggregates) have been shown to exhibit antibody activity. "Fab protein", which protein is one of the aspects of the invention, includes aggregates of one heavy and one light chain (commonly known as Fab'), as well as tetramers which correspond to the two branch segments of the antibody Y, (commonly known as F(ab)<sub>2</sub>), whether any of the above are covalently or non-covalently aggregated, so long as the aggregation is capable of selectively reacting with a particular antigen or antigen family. Fab antibodies have, been formed heretofore by proteolysis, and share the property of not eliciting antigen modulation on target tissues. However, as they lack the "effector" Fc portion they cannot effect, for example, lysis of the target cell by macrophages.

**[0025]** "Chimeric" Fab is defined analogously to the corresponding definition set forth in the previous paragraph for the Chimeric antibodies.

**[0026]** Individual heavy or light chains are "chimeric" in accordance with the above. As will become apparent from the detailed description of the invention, it is possible, using the techniques disclosed to prepare other combinations of the four-peptide chain aggregates, besides those specifically defined, such as hybrid antibodies containing chimeric light and mammalian heavy chains, hybrid Fab proteins containing chimeric Fab proteins of heavy chains associated with mammalian light chains, and so forth.

**[0027]** "Expression vector" includes vectors which are capable of expressing DNA sequences contained therein, i. e., the coding sequences are operably linked to other sequences capable of effecting their expression. It is implied, although not always explicitly stated, that these expression vectors must be replicable in the host organisms either as episomes or as an integral part of the chromosomal DNA. Clearly a lack of replicability would render them effectively inoperable. A useful, but not a necessary, element of an effective expression vector is a marker encoding sequence -- i.e. a sequence encoding a protein which results in a phenotypic property (e.g. tetracycline resistance) of the cells containing the protein which permits those cells to be readily identified. In sum, "expression vector" is given a functional definition, and any DNA sequence which is capable of effecting expression of a specified contained DNA code is included in this term, as it is applied to the specified sequence. As at present, such vectors are frequently in the form of plasmids, thus "plasmid" and "expression vector" are often used interchangeably. However, there are also described other forms of expression vectors which serve equivalent functions and which may, from time to time become known in the art

**[0028]** "Recombinant host cells" refers to cells which have been transformed with vectors constructed using recombinant DNA techniques. As defined herein, the antibody or modification thereof produced by a recombinant host cell is by virtue of this transformation, rather than in such lesser amounts, or more commonly, in such less than detectable amounts, as would be produced by the untransformed host

**[0029]** In descriptions of processes for isolation of antibodies from recombinant hosts, the terms "cell" and "cell culture" are used interchangeably to denote the source of antibody unless it is clearly specified otherwise. In other words, recovery of antibody from the "cells" may mean either from spun down whole cells, or from the cell culture containing both the medium and the suspended cells.

## B. Host Cell Cultures and Vectors

**[0030]** The vectors and methods disclosed herein are suitable for use in host cells over a wide range of prokaryotic and eukaryotic organisms.

**[0031]** In general, of course, prokaryotes are preferred for cloning of DNA sequences in constructing the vectors useful in the invention. For example, E. coli K12 strain 294 (ATCC No. 31446) is particularly useful. Other microbial strains which may be used include E. coli strains such as E. coli B, and E. coli X1776 (ATCC No. 31537). These examples are, of course, intended to be illustrative rather than limiting.

[0032] Prokaryotes may also be used for expression. The aforementioned strains, as well as *E. coli* W3110 (F<sup>-</sup>, λ<sup>-</sup>, prototrophic, ATTC No. 27325), bacilli such as *Bacillus subtilis*, and other enterobacteriaceae such as *Salmonella typhimurium* or *Serratia marcesans*, and various *Pseudomonas* species may be used.

[0033] In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, *E. coli* is typically transformed using pBR322, a plasmid derived from an *E. coli* species (Bolivar, et al., *Gene* 2: 95 (1977)). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR322 plasmid, or other microbial plasmid must also contain, or be modified to contain, promoters which can be used by the microbial organism for expression of its own proteins. Those promoters most commonly used in recombinant DNA construction include the β-lactamase (penicillinase) and lactose promoter systems (Chang et al. *Nature*, 275: 615 (1978); Itakura, et al, *Science*, 198: 1056 (1977); (Goeddel, et al *Nature* 281: 544 (1979)) and a tryptophan (trp) promoter system (Goeddel, et al, *Nucleic Acids Res.*, 8: 4057 (1980); EPO Appl Publ No. 0036776). While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling a skilled worker to ligate them functionally with plasmid vectors (Siebenlist, et al, *Cell* 20: 269 (1980)).

### C. Methods Employed

#### C.1 Transformation:

[0034] The preferred method of transfection is calcium treatment using calcium chloride as described by Cohen. F N. et al *Proc. Natl. Acad. Sci. (USA)*, 69: 2110 (1972).

#### C.2 Vector Construction

[0035] Construction of suitable vectors containing the desired coding and control sequences employ standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to form the plasmids required. The methods employed are not dependent on the DNA source, or intended host.

[0036] Cleavage is performed by treating with restriction enzyme (or enzymes) in suitable buffer. In general, about 1 μg plasmid or DNA fragments is used with about 1 unit of enzyme in about 20 μl of buffer solution. (Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer.) Incubation times of about 1 hour at 37° C are workable. After incubations, protein is removed by extraction with phenol and chloroform, and the nucleic acid is recovered from the aqueous fraction by precipitation with ethanol.

[0037] If blunt ends are required, the preparation is treated for 15 minutes at 15° with 10 units of *E. coli* DNA Polymerase I (Klenow), phenol-chloroform extracted, and ethanol precipitated.

[0038] Size separation of the cleaved fragments is performed using 6 percent polyacrylamide gel described by Goeddel, D., et al, *Nucleic Acids Res.*, 8: 4057 (1980) incorporated herein by reference.

[0039] For ligation, approximately equimolar amounts of the desired components, suitably end tailored to provide correct matching are treated with about 10 units T4 DNA ligase per 0.5 μg DNA. (When cleaved vectors are used as components, it may be useful to prevent religation of the cleaved vector by pretreatment with bacterial alkaline phosphatase.

[0040] In the examples described below correct ligations for plasmid construction are confirmed by transforming *E. coli* K12 strain 294 (ATCC 31446) with the ligation mixture. Successful transformants were selected by ampicillin or tetracycline resistance depending on the mode of plasmid construction. Plasmids from the transformants were then prepared, analyzed by restriction and/or sequenced by the method of Messing, et al, *Nucleic Acids Res.*, 9:309 (1981) or by the method of Maxam, et al, *Methods in Enzymology*, 65:499 (1980).

### D. Outline of Procedures

#### D.1 Mammalian Antibodies

[0041] The first type of antibody which is described herein is a "mammalian antibody"-one wherein the heavy and light chains are from an antibody otherwise produced by a mature mammalian B lymphocyte either *in situ* or when fused with an immortalized cell as part of a hybridoma culture. In outline, these antibodies are produced as follows:

[0042] Messenger RNA coding for heavy or light chain is isolated from a suitable source, either mature B cells or a hybridoma culture, employing standard techniques of RNA isolation, and the use of oligo-dT cellulose chromatography to segregate the poly-A mRNA. The poly-A mRNA may, further, be fractionated to obtain sequences, of sufficient size

to code for the amino acid sequences in the light or heavy chain of the desired antibody as the case may be.

**[0043]** A cDNA library is then prepared from the mixture of mRNA using a suitable primer, preferably a nucleic acid sequence which is characteristic of the desired cDNA. Such a primer may be hypothesized and synthesized based on the amino acid sequence of the antibody if the sequence is known. In the alternative cDNA from unfractionated poly-  
 5 A mRNA from a cell line producing the desired antibody or poly-dT may also be used. The resulting cDNA is optionally size fractionated on polyacrylamide gel and then extended with, for example, dC residues for annealing with pBR322 or other suitable cloning vector which has been cleaved by a suitable restriction enzyme, such as Pst I, and extended with dG residues. Alternative means of forming cloning vectors containing the cDNA using other tails and other cloning vector remainder may, of course, also be used but the foregoing is a standard and preferable choice. A suitable host  
 10 cell strain, typically *E. coli*, is transformed with the annealed cloning vectors, and the successful transformants identified by means of, for example, tetracycline resistance or other phenotypic characteristic residing on the cloning vector plasmid.

**[0044]** Successful transformants are picked and transferred to microtiter dishes or other support for further growth and preservation. Nitrocellulose filter imprints of these growing cultures are then probed with suitable nucleotide sequences containing bases known to be complementary to desired sequences in the cDNA. Several types of probe may  
 15 be used, preferably synthetic single stranded DNA sequences labeled by kinasing with ATP<sup>32</sup>. The cells fixed to the nitrocellulose filter are lysed, the DNA denatured, and then fixed before reaction with kinased probe. Clones which successfully hybridize are detected by contact with a photoplate, then plasmids from the growing colonies isolated and sequenced by means known in the art to verify that the desired portions of the gene are present.

**[0045]** The desired gene fragments are excised and tailored to assure appropriate reading frame with the control segments when inserted into suitable expression vectors. Typically, nucleotides are added to the 5' end to include a start signal and a suitably positioned restriction endonuclease site.

**[0046]** The tailored gene sequence is then positioned in a vector which contains a promoter in reading frame with the gene and compatible with the proposed host cell. A number of plasmids such as those described in U.S. Pat. Appl. Ser. Nos. 307473; 291892; and 305657 (EPO Publ. Nos. 0036776; 0048970 and 0051873) have been described which  
 25 already contain the appropriate promoters, control sequences, ribosome binding sites, and transcription termination sites, as well as convenient markers.

**[0047]** The gene coding for the light chain and that coding for the heavy chain are recovered separately by the procedures outlined above. Thus they may be inserted into separate expression plasmids, or together in the same  
 30 plasmid, so long as each is under suitable promoter and translation control.

**[0048]** The expression vectors constructed above are then used to transform suitable cells. The light and heavy chains may be transformed into separate cell cultures, either of the same or of differing species; separate plasmids for light and heavy chain may be used to co-transform a single cell culture, or, finally, a single expression plasmid containing both genes and capable of expressing the genes for both light and heavy chain may be transformed into a  
 35 single cell culture.

**[0049]** Regardless of which of the three foregoing options is chosen, the cells are grown under conditions appropriate to the production of the desired protein. Such conditions are primarily mandated by the type of promoter and control systems used in the expression vector, rather than by the nature of the desired protein. The protein thus produced is then recovered from the cell culture by methods known in the art, but choice of which is necessarily dependent on the  
 40 form in which the protein is expressed. For example, it is common for mature heterologous proteins expressed in *E. coli* to be deposited within the cells as insoluble particles which require cell lysis and solubilization in denaturant to permit recovery. On the other hand, proteins under proper synthesis circumstances, in bacterial strains, can be secreted into the medium (gram positive bacteria) or into the periplasmic space (gram negative bacteria) allowing recovery by less drastic procedures.

**[0050]** When heavy and light chain are coexpressed in the same host, the isolation procedure is designed so as to recover reconstituted antibody. This can be accomplished in vitro as described below, or might be possible in vivo in a microorganism which secretes the IgG chains out of the reducing environment of the cytoplasm. A more detailed description is given in D.2, below.

## 50 D.2 Chain Recombination Techniques

**[0051]** The ability to produce heavy and light chains or portions thereof, in isolation from each other offers the opportunity to obtain unique and unprecedented assemblies of immunoglobulins and Fab regions. Such preparations require the use of techniques to reassemble isolated chains. Such means are known in the art, and it is, thus, appropriate  
 55 to review them here.

**[0052]** While single chain disulfide bond containing proteins have been reduced and reoxidized to regenerate in high yield native structure and activity (Freedman, R.B., et al. In Enzymology of Post Translational Modification of Proteins, I: 157-212 (1980) Academic Press, NY.), proteins which consist of discontinuous polypeptide chains held together by



disulfide bonds are more difficult to reconstruct in vitro after reductive cleavage. Insulin, a cameo case, has received much experimental attention over the years, and can now be reconstructed so efficiently that an industrial process has been built around it (Chance, R.E., et al., In Peptides: Proceedings of the Seventh Annual American Peptide Symposium (Rich. D.H. and Gross. E., eds.) 721-728, Pierce Chemical Co., Rockford, IL. (1981)).

**[0053]** Immunoglobulin has proved a more difficult problem than insulin. The tetramer is stabilized intra and inter-molecularly by 15 or more disulfide bonds. It has been possible to recombine heavy and light chains, disrupted by cleavage of only the interchain disulfides, to regain antibody activity even without restoration of the inter-chain disulfides (Edelman, G.M., et al., Proc. Natl. Acad. Sci. (USA) 50: 753 (1963)). In addition, active fragments of IgG formed by proteolysis (Fab fragments of 50.000 MW) can be split into their fully reduced heavy chain and light chain components and fairly efficiently reconstructed to give active antibody (Haber, E., Proc. Natl. Acad. Sci. (USA) 52: 1099 (1964); Whitney, P.L., et al., Proc. Natl. Acad. Sci. (USA) 53: 524 (1965)). Attempts to reconstitute active antibody from fully reduced native IgG have been largely unsuccessful, presumably due to insolubility of the reduced chains and of side products or intermediates in the refolding pathway (see discussion in Freedman, M.H., et al., J. Biol. Chem. 241: 5225 (1966)). If, however, the immunoglobulin is randomly modified by polyalanylation of its lysines before complete reduction, the separated chains have the ability to recover antigen-combining activity upon reoxidation (ibid).

**[0054]** A particularly suitable method for immunoglobulin reconstitution is derivable from the now classical insulin recombination studies, wherein starting material was prepared by oxidative sulfitolysis, thus generating thiol-labile S-sulfonate groups at all cysteines in the protein, non-reductively breaking disulfides (Chance et al. (supra)). Oxidative sulfitolysis is a mild disulfide cleavage reaction (Means, G.E., et al., Chemical Modification of Proteins, Holden-Day, San Francisco (1971)) which is sometimes more gentle than reduction, and which generates derivatives which are stable until exposed to mild reducing agent at which time disulfide reformation can occur via thiol-disulfide interchange. The heavy and light chain S-sulfonates generated by oxidative sulfitolysis were reconstituted utilizing both air oxidation and thiol-disulfide interchange to drive disulfide bond formation. The general procedure is set forth in detail in U.S. Serial No. 452,187, filed Dec. 22, 1982 (EPO Appln. No. 83.307840.5), incorporated herein by reference.

### D.3 Variants Permitted by Recombinant Technology

**[0055]** Using the techniques described in paragraphs D.1 and D.2, additional operations which were utilized to gain efficient production of antibody can be varied in quite straightforward and simple ways to produce a great variety of modifications of this basic antibody form. These variations are inherent in the use of recombinant technology, which permits modification at a genetic level of amino acid sequences in normally encountered immunoglobulin chains, and the great power of this approach lies in its ability to achieve these variations, as well as in its potential for economic and specific production of desired scarce, and often contaminated, molecules. The variations also inhere in the ability to isolate production of individual chains, and thus create novel assemblies.

**[0056]** Briefly, since genetic manipulations permit reconstruction of genomic material in the process of construction of expression vectors, such reconstruction can be manipulated to produce new coding sequences for the components of "natural" antibodies or immunoglobulins. As discussed in further detail below, the coding sequence for a mammalian heavy chain may not be derived entirely from a single source or single species, but portions of a sequence can be recovered by the techniques described in D.1 from differing pools of mRNA, such as murine-murine hybridomas, human-murine hybridomas, or B cells differentiated in response to a series of antigen challenges. The desired portions of the sequences in each case can be recovered using the probe and analysis techniques described in D.1, and recombined in an expression vector using the same ligation procedures as would be employed for portions of the same model sequence. Such chimeric chains can be constructed of any desired length; hence, for example, a complete heavy chain can be constructed, or only sequence for the Fab region thereof.

**[0057]** The additional area of flexibility which arises from the use of recombinant techniques results from the power to produce heavy and light chains or fragments thereof in separate cultures or of unique combinations of heavy and light chain in the same culture, and to prevent reconstitution of the antibody or immunoglobulin aggregation until the suitable components are assembled. Thus, while normal antibody production results automatically in the formation of "mammalian antibodies" because the light and heavy chain portions are constructed in response to a particular determinant in the same cell, the methods of the present invention present the opportunity to assemble entirely new mixtures. Somewhat limited quantities of "hybrid" antibodies have been produced by "quadromas" i.e., fusions of two hybridoma cell cultures which permit random assemblies of the heavy and light chains so produced.

**[0058]** A more controlled assembly of desired chains is permitted, either by mixing the desired chains in vitro, or by transforming the same culture with the coding sequences for the desired chains. each other and mismatched to another pair gives the desired hybrid antibody.



D.4 Chimeric Antibodies

**[0059]** For construction of chimeric antibodies (wherein, for example, the variable sequences are separately derived from the constant sequences) the procedures of paragraph D.1 and D.2 are again applicable with appropriate additions and modifications. A preferred procedure is to recover desired portions of the genes encoding for parts of the heavy and light chains from suitable, differing, sources and then to religate these fragments using restriction endonucleases to reconstruct the gene coding for each chain.

**[0060]** For example, in a particularly preferred chimeric construction, portions of the heavy chain gene and of the light chain gene which encode the variable sequences of antibodies produced by a murine hybridoma culture are recovered and cloned from this culture and gene fragments encoding the constant regions of the heavy and light chains for human antibodies recovered and cloned from, for example, human myeloma cells. Suitable restriction enzymes may then be used to ligate the variable portions of the mouse gene to the constant regions of the human gene for each of the two chains. The chimeric chains are produced as set forth in D.1, aggregated as set forth in D.2 and used in the same manner as the non-chimeric forms. Of course, any splice point in the chains can be chosen.

D.5 Fab Protein

**[0061]** Similarly, it is not necessary to include the entire gene for the heavy chain portion. All of the aforementioned variations can be superimposed on a procedure for Fab protein production and the overall procedure differs only in that that portion of the heavy chain coding for the amino terminal 220 amino acids is employed in the appropriate expression vector.

E. Specific Examples of Preferred Embodiments

**[0062]** The above description is in general terms and there follow several specific examples of embodiments which set forth details of experimental procedure in producing the desired antibodies. Example E.1 sets forth the general procedure for preparing anti CEA antibody components. Example E.3 sets forth the procedure for reconstitution and thus is applicable to preparation of chimeric immunoglobulins, and Fab proteins. Example E.4 sets forth the procedure for tailoring the heavy or light chain so that the variable and constant regions may be derived from different sources. Example E.5 sets forth the method of obtaining a shortened heavy chain genome which permits the production of the Fab regions and, in an analogous manner, Fc region.

E.1 Construction of Expression Vectors for Murine anti-CEA Antibody Chains and Peptide Synthesis

**[0063]** Carcinoembryonic antigen (CEA) is associated with the surface of certain tumor cells of human origin (Gold, P., et al., J. Med., 122: 467 (1965)). Antibodies which bind to CEA (anti-CEA antibodies) are useful in early detection of these tumors (Van Nagell, T.R., et al., Cancer Res. 40: 502 (1980)), and have the potential for use in treatment of those human tumors which appear to support CEA at their surfaces. A mouse hybridoma cell line which secretes anti-CEA antibodies of the IgY<sub>1</sub> class, CEA.66-E3, has been prepared as described by Wagener, C. et al., J. Immunol. 130, 2308 (1983) which is incorporated herein by reference, and was used as mRNA source. The production of anti CEA antibodies by this cell line was determined. The N-terminal sequences of the antibodies produced by these cells was compared with those of monoclonal anti CEA as follows. Purified IgG was treated with PCAse (Podell, D.N., et al., Biochem. Biophys. Res. Commun. 81: 176 (1978)), and then dissociated in 6M guanidine hydrochloride, 10 mM 2-mercaptoethanol (1.0 mg of immunoglobulin, 5 min, 100° C water bath). The dissociated chains were separated on a Waters Associates alkyl phenyl column using a linear gradient from 100 percent A (0.1 percent TFA-water) to 90 percent B (TFA/H<sub>2</sub>O/MeCN 0.1/9.9/90) at a flow rate of 0.8 ml/min. Three major peaks were eluted and analyzed on SDS gels by silver staining. The first two peaks were pure light chain (Mu 25,000 daltons), the third peak showed a (7:3) mixture of heavy and light chain. 1.2 nmoles of light chain were sequenced by the method of Shively, J.E., Methods in Enzymology, 79: 31 (1981), with an NH<sub>2</sub>-terminal yield of 0.4 nmoles. A mixture of heavy and light chains (3 nmoles) was also sequenced, and sequence of light chain was deducted from the double sequence to yield the sequence of the heavy chain.

**[0064]** In the description which follows, isolation and expression of the genes for the heavy and light chains for anti CEA antibody produced by CEA.66-E3 are described. As the constant regions of these chains belong to the gamma and kappa families, respectively, "light chain" and "kappa chain", and "heavy chain" and "gamma chain", respectively, are used interchangeably below.

E.1.1 Isolation of Messenger RNA for Anti CEA Light and Heavy (Kappa and Gamma) Chains

**[0065]** Total RNA from CEA.66-E3 cells was extracted essentially as reported by Lynch et al, Virology, 98: 251 (1979). Cells were pelleted by centrifugation and approximately 1 g portions of pellet resuspended in 10 ml of 10 mM NaCl, 10 mM Tris HCl (pH 7.4), 1.5 mM MgCl<sub>2</sub>. The resuspended cells were lysed by addition of non-ionic detergent NP-40 to a final concentration of 1 percent, and nuclei removed by centrifugation. After addition of SDS (pH 7.4) to 1 percent final concentration, the supernatant was extracted twice with 3 ml portions of phenol (redistilled)/chloroform: isoamyl alcohol 25:1 at 4°C. The aqueous phase was made 0.2 M in NaCl and total RNA was precipitated by addition of two volumes of 100 percent ethanol and overnight storage at -20°C. After centrifugation, polyA mRNA was purified from total RNA by oligo-dT cellulose chromatography as described by Aviv and Leder, Proc. Nat'l. Acad. Sci. (USA), 69: 1408 (1972). 142 µg of polyA mRNA was obtained from 1 g cells.

E.1.2 Preparation of E. coli Colony Library Containing Plasmids with Heavy and Light DNA Sequence Inserts

**[0066]** 5 µg of the unfractionated polyA mRNA prepared in paragraph E.1.1 was used as template for oligo-dT primed preparation of double-stranded (ds) cDNA by standard procedures as described by Goeddel et al., Nature 281: 544 (1979) and Wickens et al., J. Biol. Chem. 253: 2483 (1978) incorporated herein by reference. The cDNA was size fractionated by 6 percent polyacrylamide gel electrophoresis and 124 ng of ds cDNA greater than 600 base pairs in length was recovered by electroelution. A 20 ng portion of ds cDNA was extended with deoxy C residues using terminal deoxynucleotidyl transferase as described in Chang et al., Nature 275: 617 (1978) incorporated herein by reference, and annealed with 200 ng of the plasmid pBR322 (Bolivar et al., Gene 2: 95 (1977)) which had been cleaved with Pst I and tailed with deoxy G. Each annealed mixture was then transformed into E. coli K12 strain 294 (ATCC No. 31446). Approximately 8500 ampicillin sensitive, tetracycline resistant transformants were obtained.

E.1.3 Preparation of Synthetic Probes

**[0067]** The 14mer, 5' GGTGGGAAGATGGA 3' complementary to the coding sequence of constant region for mouse MOPC21 kappa chain which begins 25 basepairs 3' of the variable region DNA sequence was used as kappa chain probe. A 15 mer, 5' GACCAGGCATCCCAG 3' complementary to a coding sequence located 72 basepairs 3' of the variable region DNA sequence for mouse MOPC21 gamma chain was used to probe gamma chain gene.

**[0068]** Both probes were synthesized by the phosphotriester method described in German Offenlegungsschrift 2644432, incorporated herein by reference, and made radioactive by kinasing as follows: 250 ng of deoxyoligonucleotide were combined in 25 µl of 60 mM Tris HCl (pH 8), 10 mM MgCl<sub>2</sub>, 15 mM betamercaptoethanol, and 100 µCi (γ-<sup>32</sup>P) ATP (Amersham, 5000 Ci.mMole). 5 units of T4 polynucleotide kinase were added and the reaction was allowed to proceed at 37°C for 30 minutes and terminated by addition of EDTA to 20 mM.

E.1.4 Screening of Colony Library for Kappa or Gamma Chain Sequences

**[0069]** ~2000 colonies prepared as described in paragraph E.1.2 were individually inoculated into wells of microtitre dishes containing LB (Miller, Experiments in Molecular Genetics, p. 431-3, Cold Spring Harbor Lab., Cold Spring Harbor, New York (1972)) + 5 µg, ml tetracycline and stored at -20°C after addition of DMSO to 7 percent. Individual colonies from this library were transferred to duplicate sets of Schleicher and Schuell BA85/20 nitrocellulose filters and grown on agar plates containing LB + 5 µg ml tetracycline. After ~10 hours growth at 37°C the colony filters were transferred to agar plates containing LB + 5 µg ml tetracycline and 12.5 µg/ml chloramphenicol and reincubated overnight at 37°C. The DNA from each colony was then denatured and fixed to the filter by a modification of the Grunstein-Hogness procedure as described in Grunstein et al., Proc. Natl. Acad. Sci. (USA) 72: 3961 (1975), incorporated herein by reference. Each filter was floated for 3 minutes on 0.5 N NaOH, 1.5 M NaCl to lyse the colonies and denature the DNA then neutralized by floating for 15 minutes on 3 M NaCl, 0.5 M Tris HCl (pH 7.5). The filters were then floated for an additional 15 minutes on 2XSSC, and subsequently baked for 2 hours in an 80°C vacuum oven. The filters were prehybridized for ~2 hours at room temperature in 0.9 M NaCl, 1X Denhardt's, 100 mM Tris HCl (pH 7.5), 5 mM Na-EDTA, 1 mM ATP, 1 M sodium phosphate (dibasic), 1 mM sodium pyrophosphate, 0.5 percent NP-40, and 200 µg/ml E. coli t-RNA, and hybridized in the same solution overnight, essentially as described by Wallace et al., Nucleic Acids Research 9: 879 (1981) using -40×10<sup>6</sup> cpm of either the kinased kappa or gamma probe described above.

**[0070]** After extensive washing at 37°C in 6X SSC, 0.1 percent SDS, the filters were exposed to Kodak XR-5 X-ray film with DuPont Lightning-Plus intensifying screens for 124 hours at -80°C. Approximately 20 colonies which hybridized with kappa chain probe and 20 which hybridized with gamma chain probe were characterized.

E.1.5 Characterization of Colonies which Hybridize to Kappa DNA Sequence Probe

**[0071]** Plasmid DNAs isolated from several different transformants which hybridized to kappa chain probe were cleaved with Pst I and fractionated by polyacrylamide gel electrophoresis (PAGE). This analysis demonstrated that a number of plasmid DNAs contained cDNA inserts large enough to encode full length kappa chain. The complete nucleotide sequence of the cDNA insert of one of these plasmids was determined by the dideoxynucleotide chain termination method as described by Smith, *Methods Enzymol.* 65, 560 (1980) incorporated herein by reference after sub-cloning restriction endonuclease cleavage fragments into M13 vectors (Messing et al., *Nucleic Acids Research* 9: 309 (1981). Figure 2 shows the nucleotide sequence of the cDNA insert of pK17G4 and Figure 3 shows the gene sequence with the corresponding amino acid sequence. Thus, the entire coding region of mouse anti-CEA kappa chain was isolated on this one large DNA fragment. The amino acid sequence of kappa chain, deduced from the nucleotide sequence of the pK17G4 cDNA insert, corresponds perfectly with the first 23 N-terminal amino acids of nature mouse anti-CEA kappa chain as determined by amino acid sequence analysis of purified mouse anti-CEA kappa chain. The coding region of pK17G4 contains 27 basepairs or 9 amino acids of the presequence and 642 basepairs or 214 amino acids of the mature protein. The mature unglycosylated protein (MW 24.553) has a variable region of 119 amino acids, including the J1 joining region of 12 amino acids, and a constant region of 107 amino acids. After the stop codon behind amino acid 215 begins 212 basepairs of 3' untranslated sequence up to the polyA addition. The kappa chain probe used to identify pK17G4 hybridizes to nucleotides 374-388 (figure 2).

E.1.6 Characterization of Colonies which Hybridize to Gamma 1 DNA Probe

**[0072]** Plasmid DNA isolated from several transformants positive for hybridization with the heavy chain gamma 1 probe was subjected to Pst I restriction endonuclease analysis as described in E.1.5. Plasmid DNAs demonstrating the largest cDNA insert fragments were selected for further study. Nucleotide sequence coding for mouse heavy (gamma-1) chain, shows an NcoI restriction endonuclease cleavage site near the junction between variable and constant region. Selected plasmid DNAs were digested with both PstI and NcoI and sized on polyacrylamide. This analysis allowed identification of a number of plasmid DNAs that contain NcoI restriction endonuclease sites, although none that demonstrate cDNA insert fragments large enough to encode the entire coding region of mouse anti-CEA heavy chain.

**[0073]** In one plasmid isolated, p $\gamma$ 298 the cDNA insert of about 1300 bp contains sequence information for the 5' untranslated region, the signal sequence and the N-terminal portion of heavy chain. Because p $\gamma$ 298 did not encode the C-terminal sequence for mouse anti-CEA gamma 1 chain, plasmid DNA was isolated from other colonies and screened with PstI and NcoI. The C-terminal region of the cDNA insert of p $\gamma$ 11 was sequenced and shown to contain the stop codon, 3' untranslated sequence and that portion of the coding sequence missing from p $\gamma$ 298.

**[0074]** Figure 4 presents the entire nucleotide sequence of mouse anti-CEA heavy chain (as determined by the dideoxynucleotide chain termination method of Smith, *Methods Enzymol.*, 65: 560 (1980)) and Figure 5 includes the translated sequence.

**[0075]** The amino acid sequence of gamma 1 (heavy chain) deduced from the nucleotide sequence of the p $\gamma$ 298 cDNA insert corresponds perfectly to the first 23 N-terminal amino acids of mature mouse anti-CEA gamma 1 chain as determined by amino acid sequence analysis of purified mouse anti-CEA gamma-1 chain. The coding region consists of 57 basepairs or 19 amino acids of presequences and 1346 basepairs or 447 amino acids of mature protein. The mature unglycosylated protein (MW 52.258) has a variable region of 135 amino acids, including a D region of 12 amino acids, and a J4 joining region of 13 amino acids. The constant region is 324 amino acids. After the stop codon behind amino acid 447 begins 96 bp of 3' untranslated sequences up to the polyA addition. The probe used to identify P $\gamma$ 298 and P $\gamma$ 11 hybridized to nucleotides 528-542 (Figure 4).

E.1.7 Construction of a Plasmid For Direct Expression of Mouse Mature Anti-CEA Kappa Chain Gene, pKCEAtrp207-1\*

**[0076]** Figure 6 illustrates the construction of pKCEAtrp207-1\*

**[0077]** First, an intermediate plasmid pHGH207-1\*, having a single trp promoter, was prepared as follows:

**[0078]** The plasmid pHGH 207 (described in U.S. Pat Appl. Serial No. 307,473, filed Oct. 1, 1981 (EPO Publn. No. 0036776)) has a double lac promoter followed by the trp promoter, flanked by EcoR I sites and was used to prepare pHGH207-1. pHGH207 was digested with BamH I, followed by partial digestion with EcoR I. The largest fragment, which contains the entire trp promoter, was isolated and ligated to the largest EcoR I- BamH I fragment from pBR322, and the ligation mixture used to transform *E. coli* 294. Tet<sup>R</sup> Amp<sup>R</sup> colonies were isolated, and most of them contained pHGH207-1. pHGH207-1\* which lacks the EcoR1 site between the amp<sup>R</sup> gene and the trp promoter, was obtained by partial digestion of pHGH207-1 with EcoR I, filling in the ends with Klenow and dNTPs, and religation.

**[0079]** 5  $\mu$ g of pHGH207-1\* was digested with EcoRI, and the ends extended to blunt ends using 12 units of DNA



Polymerase I in a 50  $\mu$ l reaction containing 60 mM NaCl, 7 mM MgCl<sub>2</sub>, 7 mM Tris HCl (pH 7.4) and 1 mM in each dNTP at 37°C for 1 hour, followed by extraction with phenol/CHCl<sub>3</sub> and precipitation with ethanol. The precipitated DNA was digested with BamH I, and the large vector fragment (fragment 1) purified using 5 percent polyacrylamide gel electrophoresis, electroelution, phenol/CHCl<sub>3</sub> extraction and ethanol precipitation.

**[0080]** The DNA was resuspended in 50  $\mu$ l of 10 mM Tris pH 8, 1 mM EDTA and treated with 500 units Bacterial Alkaline Phosphatase (BAP) for 30' at 65° followed by phenol/CHCl<sub>3</sub> extraction and ethanol precipitation.

**[0081]** A DNA fragment containing part of the light chain sequence was prepared as follows: 7  $\mu$ g of pK17G4 DNA was digested with Pst I and the kappa chain containing cDNA insert was isolated by 6 percent gel electrophoresis, and electroelution. After phenol/CHCl<sub>3</sub> extraction, ethanol precipitation and resuspension in water, this fragment was digested with Ava II. The 333 bp Pst I-Ava II DNA fragment was isolated and purified from a 6 percent polyacrylamide gel.

**[0082]** A 15 nucleotide DNA primer was synthesized by the phosphotriester method G. O. 2.644.432 (supra) and has the following sequence: Met Asp Ile Val Met

5' ATG GAC ATT GTT ATG 3'

**[0083]** The 5' methionine serves as the initiation codon. 500 ng of this primer was phosphorylated at the 5' end with 10 units T4 DNA kinase in 20  $\mu$ l reaction containing 0.5 mM ATP. ~200 ng of the Pst I-Ava II DNA fragment was mixed with the 20  $\mu$ l of the phosphorylated primer, heated to 95°C for 3 minutes and quick frozen in a dry-ice ethanol bath. The denatured DNA solution was made 60mM NaCl, 7mM MgCl<sub>2</sub>, 7 mM Tris HCl (pH 7.4), 12 mM each dNTP and 12 units DNA Polymerase I-Large Fragment was added. After 2 hours incubation at 37°C this primer repair reaction was phenol, CHCl<sub>3</sub> extracted, ethanol precipitated, and digested to completion with Sau 3A. The reaction mixture was then electrophoresed on a 6 percent polyacrylamide gel and ~50 ng of the 182 basepair amino-terminal blunt-end to Sau 3A fragment (fragment 2) was obtained after electroelution.

**[0084]** 100 ng of fragment 1 (supra) and 50 ng of fragment 2 were combined in 20  $\mu$ l of 20 mM Tris HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, 10 mM DTT, 2.5 mM ATP and 1 unit of T4 DNA ligase. After overnight ligation at 14°C the reaction was transformed into *E. coli* K12 strain 294, Restriction endonuclease digestion of plasmid DNA from a number of ampicillin resistant transformants indicated the proper construction and DNA sequence analysis proved the desired nucleotide sequence through the initiation codon of this new plasmid, pKCEAInt1 (Figure 6).

**[0085]** The remainder of the coding sequence of the kappa light chain gene was prepared as follows:

**[0086]** The Pst I cDNA insert fragment from 7  $\mu$ g of K17G4 DNA was partially digested with Ava II and the Ava II cohesive ends were extended to blunt ends in a DNA Polymerase I large fragment reaction. Following 6 percent polyacrylamide gel electrophoresis the 686 basepair Pst I to blunt ended Ava II DNA fragment was isolated, purified and subjected to Hpa II restriction endonuclease digestion. The 497 basepair Hpa II to blunt ended Ava II DNA fragment (fragment 3) was isolated and purified after gel electrophoresis.

**[0087]** 10  $\mu$ g of pKCEAInt1 DNA was digested with Ava I, extended with DNA polymerase I large fragment, and digested with Xba I. Both the large blunt ended Ava I to Xba I vector fragment and the small blunt ended Ava I to Xba I fragment were isolated and purified from a 6 percent polyacrylamide gel after electrophoresis. The large vector fragment (fragment 4) was treated with Bacterial Alkaline Phosphatase (BAP), and the small fragment was digested with Hpa II, electrophoresed on a 6 percent polyacrylamide and the 169 basepair Xba I-Hpa II DNA fragment (fragment 5) was purified. ~75 ng of fragment 4, ~50 ng of fragment 3 and ~50 ng of fragment 5 were combined in a T4 DNA ligase reaction and incubated overnight at 14°, and the reaction mixture transformed into *E. coli* K12 strain 294. Plasmid DNA from six ampicillin resistant transformants were analyzed by restriction endonuclease digestion. One plasmid DNA demonstrated the proper construction and was designated pKCEAInt2.

**[0088]** Final construction was effected by ligating the K-CEA fragment, including the trp promoter from pKCEAInt2 into pBR322(XAP). (pBR322(XAP) is prepared as described in U.S. Application 452.227, filed December 22, 1982; from pBR322 by deletion of the Aval-PvuII fragment followed by ligation.)

**[0089]** The K-CEA fragment was prepared by treating pKCEAInt2 with Ava I, blunt ending with DNA polymerase I (Klenow fragment) in the presence of DNTPs, digestion with Pst I and isolation of the desired fragment by gel electrophoresis and electroelution.

**[0090]** The large vector fragment from pBR322(XAP) was prepared by successive treatment with EcoR I, blunt ending with polymerase, and redigestion with Pst I, followed by isolation of the large vector fragment by electrophoresis and electroelution.

**[0091]** The K-CEA and large vector fragments as prepared in the preceding paragraphs were ligated with T4 DNA ligase, and the ligation mixture transformed into *E. coli* as above. Plasmid DNA from several ampicillin resistant transformants were selected for analysis, and one plasmid DNA demonstrated the proper construction, and was designated pKCEAtrp207-I\*.



### E.1.8 Construction of a Plasmid Vector for Direct Expression of Mouse Mature Anti-CEA Heavy (Gamma 1) Chain Gene, *pyCEAtrp207-1\**

**[0092]** Figure 7 illustrates the construction of *pyCEAtrp207-1\**. This plasmid was constructed in two parts beginning with construction of the C-terminal region of the gamma 1 gene.

**[0093]** 5 µg of plasmid pHGH207-1\* was digested with *Ava* I, extended to blunt ends with DNA polymerase I large fragment (Klenow fragment), extracted with phenol CHCl<sub>3</sub>, and ethanol precipitated. The DNA was digested with *Bam*HI treated with BAP and the large fragment (fragment A) was purified by 6 percent polyacrylamide gel electrophoresis and electroelution,

**[0094]** ~5 µg of *py11* was digested with *Pst* I and the gamma chain cDNA insert fragment containing the C-terminal portion of the gene was purified, digested with *Ava* II followed by extension of the *Ava* II cohesive ends with Klenow, followed by *Taq* I digestion. The 375 basepair blunt ended *Ava* II to *Taq* I fragment (fragment B) was isolated and purified by gel electrophoresis and electroelution.

**[0095]** 9 µg of *py298* was digested with *Taq* I and *Bam*HI for isolation of the 496 basepair fragment (fragment C).

**[0096]** Approximately equimolar amounts of fragments A, B, and C were ligated overnight at 14° in 20µl reaction mixture, then transformed into *E. coli* strain 294. The plasmid DNA from six ampicillin resistant transformants was committed to restriction endonuclease analysis and one plasmid DNA, named *pyCEAInt*, demonstrated the correct construction of the C-terminal portion of gamma 1 (Figure 5).

**[0097]** To obtain the N-terminal sequences, 30 µg of *py298* was digested with *Pst* I and the 628 basepair DNA fragment encoding the N-terminal region of mouse anti-CEA gamma chain was isolated and purified. This fragment was further digested with *Alu* I and *Rsa* I for isolation of the 280 basepair fragment. A 15 nucleotide DNA primer met glu val met leu

5' ATG GAA GTG ATG CTG 3'

was synthesized by the phosphotriester method (supra).

**[0098]** The 5' methionine serves as the initiation codon. 500 ng of this synthetic oligomer primer was phosphorylated at the 5' end in a reaction with 10 units T4 DNA kinase containing 0.5 mM ATP in 20µl reaction mixture. ~500 ng of the 280 basepair *Alu* I-*Rsa* I DNA fragment was mixed with the phosphorylated primer. The mixture was heat denatured for 3 minutes at 95° and quenched in dry-ice ethanol. The denatured DNA solution was made 60mM NaCl, 7mM MgCl<sub>2</sub>, 7 mM Tris HCl (pH 7.4), 12 mM in each dNTP and 12 units DNA Polymerase I-Large Fragment was added. After 2 hours incubation at 37°C, this primer repair reaction was phenol/CHCl<sub>3</sub> extracted, ethanol precipitated, and digested to completion with *Hpa*II. ~50 ng of the expected 125 basepair blunt-end to *HPa* II DNA fragment (fragment D) was purified from the gel.

**[0099]** A second aliquot of *py298* DNA was digested with *Pst* I, the 628 basepair DNA fragment purified by polyacrylamide gel electrophoresis, and further digested with *Bam*HI and *Hpa* II. The resulting 380 basepair fragment (fragment E) was purified by gel electrophoresis.

**[0100]** ~5 µg of *pyCEAInt1* was digested with *Eco*R I, the cohesive ends were made flush with DNA polymerase I (Klenow), further digested with *Bam*HI, treated with BAP and electrophoresed on a 6 percent polyacrylamide gel. The large vector fragment (fragment F) was isolated and purified.

**[0101]** In a three fragment ligation, 50 ng fragment D, 100 ng fragment E, and 100 ng fragment F were ligated overnight at 4° in a 20 µl reaction mixture and used to transform *E. coli* K12 strain 294. The plasmid DNAs from 12 ampicillin resistant transformants were analyzed for the correct construction and the nucleotide sequence surrounding the initiation codon was verified to be correct for the plasmid named *pyCEAInt2*.

**[0102]** The expression plasmid, *pyCEAtrp207-1\** used for expression of the heavy chain gene is prepared by a 3-way ligation using the large vector fragment from pBR322(XAP) (supra) and two fragments prepared from *pyCEAInt2*.

**[0103]** pBR322(XAP) was treated as above by digestion with *Eco*R I, blunt ending with DNA polymerase (Klenow) in the presence of dNTPs, followed by digestion with *Pst* I, and isolation of the large vector fragment by gel electrophoresis. A 1543 base pair fragment from *pyCEAInt2* containing *trp* promoter linked with the N-terminal coding region of the heavy chain gene was isolated by treating *pyCEAInt2* with *Pst* I followed by *Bam*HI, and isolation of the desired fragment using PAGE. The 869 base pair fragment containing the C-terminal coding portion of the gene was prepared by partial digestion of *pyCEAInt2* with *Ava* I, blunt ending with Klenow, and subsequent digestion with *Bam*HI, followed by purification of the desired fragment by gel electrophoresis.

**[0104]** The aforementioned three fragments were then ligated under standard conditions using T4 DNA ligase, and a ligation mixture used to transform *E. coli* strain 294. Plasmid DNAs from several tetracycline resistant transformants were analyzed; one plasmid DNA demonstrated the proper construction and was designated *pyCEAtrp207-1\**.

### E.1.9 Production of Immunoglobulin Chains by *E. coli*

**[0105]** *E. coli* strain W3110 (ATTC No. 27325) was transformed with *pyCEAtrp207-1\** or *pKCEAtrp207-1\** using stand-

ard techniques.

**[0106]** To obtain double transformants, *E. coli* strain W3110 cells were transformed with a modified pKCEAtrp207-1\*, pKCEAtrp207-1\*Δ, which had been modified by cleaving a Pst I-Pvu I fragment from the amp<sup>R</sup> gene and religating. Cells transformed with pKCEAtrp207-1\*Δ are thus sensitive to ampicillin but still resistant to tetracycline. Successful transformants were retransformed using pγCEAInt2 which confers resistance to ampicillin but not tetracycline. Cells containing both pKCEAtrp207-1\*Δ and pγCEAInt2 thus identified by growth in a medium containing both ampicillin and tetracycline.

**[0107]** To confirm the production of heavy and/or light chains in the transformed cells, the cell samples were inoculated into M9 tryptophan free medium containing 10μg/ml tetracycline, and induced with indoleacrylic acid (IAA) when the OD 550 reads 0.5. The induced cells were grown at 37°C during various time periods and then spun down, and suspended in TE buffer containing 2 percent SDS and 0.1 M β-mercaptoethanol and boiled for 5 minutes. A 10 x volume of acetone was added and the cells kept at 22°C for 10 minutes, then centrifuged at 12,000 rpm. The precipitate was suspended in O'Farrell SDS sample buffer (O'Farrell, P.H., *J. Biol. Chem.*, 250: 4007 (1975)); boiled 3 minutes, recentrifuged, and fractionated using SDS PAGE (10 percent), and stained with silver stain (Goldman, D. *et al.*, *Science* 211: 1437 (1981)); or subjected to Western blot using rabbit anti-mouse IgG (Burnett, W. N., *et al.*, *Anal. Biochem.* 112: 195 (1981)), for identification light chain and heavy chain.

**[0108]** Cells transformed with pγCEAtrp207-1\* showed bands upon SDS PAGE corresponding to heavy chain molecular weight as developed by silver stain. Cells transformed with pKCEAtrp207-1\* showed the proper molecular weight band for light chain as identified by Western Blot: double transformed cells showed bands for both heavy and light chain molecular weight proteins when developed using rabbit anti-mouse IgG by Western blot. These results are shown in Figures 8A, 8B, and 8C.

**[0109]** Figure 8A shows results developed by silver stain from cells transformed with pγCEAtrp207-1\*. Lane 1 is monoclonal anti-CEA heavy chain (standard) from CEA.66-E3. Lanes 2b-5b are timed samples 2 hrs, 4 hrs, 6 hrs, and 24 hrs after IAA addition. Lanes 2a-5a are corresponding untransformed controls; Lanes 2c-5c are corresponding uninduced transformants.

**[0110]** Figure 8B shows results developed by Western blot from cells transformed with pKCEAtrp207-1\*. Lanes 1b-6b are extracts from induced cells immediately, 1hr, 3.5 hrs, 5 hrs, 8 hrs, and 24 hrs after IAA addition, and 1a-6a corresponding uninduced controls. Lane 7 is an extract from a pγCEAtrp207-1\* control, lanes 8, 9, and 10 are varying amounts of anti CEA-kappa chain from CEA.66-E3 cells.

**[0111]** Figure 8C shows results developed by Western blot from four colonies of double transformed cells 24 hours after IAA addition (lanes 4-7). Lanes 1-3 are varying amounts of monoclonal gamma chain controls, lanes 6 and 9 are untransformed and pγCEAtrp207-1\* transformed cell extracts, respectively.

**[0112]** In another quantitative assay, frozen, transformed *E. coli* cells grown according to E.1.10 (below) were lysed by heating in sodium dodecyl sulfate (SDS)/β-mercaptoethanol cell lysis buffer at 100°. Aliquots were loaded on an SDS polyacrylamide gel next to lanes loaded with various amounts of hybridoma anti-CEA. The gel was developed by the Western blot. Burnett (supra), using <sup>125</sup>I-labeled sheep anti-mouse IgG antibody from New England Nuclear. The results are shown in Figure 9. The figure shows that the *E. coli* products co-migrate with the authentic hybridoma chains, indicating no detectable proteolytic degradation in *E. coli*. Heavy chain from mammalian cells is expected to be slightly heavier than *E. coli* material due to glycosylation in the former. Using the hybridoma lanes as a standard, the following estimates of heavy and light chain production were made:

	(Per gram of cells)
<i>E. coli</i> (W3110/pγCEAtrp207-1*)	5 mg γ
<i>E. coli</i> (W3110/pKCEAtrp207-1*)	1.5 mg K
<i>E. coli</i> (W3110/pKCEAtrp207-1*Δ, pγCEAInt2)	0.5 mg K, 1.0 mg γ

#### E.1.10 Reconstitution of Antibody from Recombinant K and Gamma Chains

**[0113]** In order to obtain heavy and light chain preparations for reconstitution, transformed cells were grown in larger batches, harvested and frozen. Conditions of growth of the variously transformed cells were as follows:

**[0114]** *E. coli* (W3110/pγCEAtrp207-1\* were inoculated into 500 ml LB medium containing 5μg/ml tetracycline and grown on a rotary shaker for 8 hours. The culture was then transferred to 10 liters of fermentation medium containing yeast nutrients, salts, glucose, and 2μg/ml tetracycline. Additional glucose was added during growth aid at OD 550 = 20, indoleacrylic (IAA), a trp derepressor, was added to a concentration of 50 μg/ml. The cells were fed additional glucose to a final OD 550 = 40, achieved approximately 6 hours from the IAA addition.

**[0115]** *E. coli* (W3110) cells transformed with pKCEAtrp207-1\* and double transformed (with pKCEAtrp207-1\*Δ and pγCEAInt2) were grown in a manner analogous to that described above except that the OD 550 six hours after

IAA addition at harvest was 25-30.

[0116] The cells were then harvested by centrifugation, and frozen.

## E.2 Assay Method for Reconstituted Antibody

[0117] Anti-CEA activity was determined by ELISA as a criterion for successful reconstitution. Wells of microtiter plates (Dynatech Immulon) were saturated with CEA by incubating 100  $\mu$ l of 2-5  $\mu$ g CEA/ml solution in 0.1 M carbonate buffer, pH 9.3 for 12 hours at room temperature. The wells were then washed 4 times with phosphate buffered saline (PBS), and then saturated with BSA by incubating 200  $\mu$ l of 0.5 percent BSA in PBS for 2 hours at 37°C, followed by washing 4 times with PBS. Fifty microliters of each sample was applied to each well. A standard curve (shown in Figure 10), was run, which consisted of 50  $\mu$ l samples of 10  $\mu$ g, 5  $\mu$ g, 1  $\mu$ g, 500 ng, 100 ng, 50 ng, 10 ng, 5 ng and 1 ng anti-CEA/ml in 0.5 percent BSA in PBS, plus 50  $\mu$ l of 0.5 percent BSA in PBS alone as a blank. All of the samples were incubated in the plate for 90 minutes at 37°C.

[0118] The plates were then washed 4 times with PBS, and sheep anti-mouse IgG-alkaline phosphate (TAGO, Inc.) was applied to each well by adding 100  $\mu$ l of an enzyme concentration of 24 units/ml in 0.5 percent BSA in PBS. The solution was incubated at 37°C for 90 minutes. The plates were washed 4 times with PBS before adding the substrate. 100  $\mu$ l of a 0.4 mg/ml solution of p-nitrophenylphosphate (Sigma) in ethanolamine buffered saline, pH 9.5. The substrate was incubated 90 minutes at 37°C for color development.

[0119] The  $A_{450}$  of each well was read by the Microelisa Auto Reader (Dynatech) set to a threshold of 1.5, calibration of 1.0 and the 0.5 percent BSA in PBS (Blank) well set to 0.000. The  $A_{450}$  data was tabulated in RS-1 on the VAX system, and the standard curve data fitted to a four-parameter logistic model. The unknown samples concentrations were calculated based on the  $A_{450}$  data.

## E.3 Reconstitution of Recombinant Antibody and Assay

[0120] Frozen cells prepared as described in paragraph E.1.10 were thawed in cold lysis buffer [10mM Tris HCl, pH 7.5, 1mM EDTA, 0.1 M NaCl, 1mM phenylmethylsulfonyl fluoride (PMSF)] and lysed by sonication. The lysate was partially clarified by centrifugation for 20 mins at 3,000 rpm. The supernatant was protected from proteolytic enzymes by an additional 1 mM PMSF, and used immediately or stored frozen at -80°C; frozen lysates were never thawed more than once.

[0121] The S-sulfonate of *E. coli* produced anti-CEA heavy chain ( $\gamma$ ) was prepared as follows: Recombinant *E. coli* cells transformed with p $\gamma$ CEAtrp207-1\* which contained heavy chain as insoluble bodies, were lysed and centrifuged as above; the pellet was resuspended in the same buffer, sonicated and re-centrifuged. This pellet was washed once with buffer, then suspended in 6M guanidine HCl, 0.1M Tris HCl, pH 8, 1mM EDTA, 20 mg/ml sodium sulfite and 10 mg/ml sodium tetrathionate and allowed to react at 25° for about 16 hrs. The reaction mixture was dialyzed against 8M urea, 0.1 M Tris HCl, pH 8, and stored at 4°, to give a 3 mg/ml solution of  $\gamma$ -SSO<sub>3</sub>.

[0122] 650  $\mu$ l of cell lysate from cells of various *E. coli* strains producing various IgG chains, was added to 500 mg urea. To this was added  $\beta$ -mercaptoethanol to 20mM, Tris-HCl, pH 8.5 to 50mM and EDTA to 1mM, and in some experiments,  $\gamma$ -SSO<sub>3</sub> was added to 0.1 mg/ml. After standing at 25° for 30-90 mins., the reaction mixtures were dialyzed at 4° against a buffer composed of 0.1M sodium glycinate, pH 10.8, 0.5M urea, 10mM glycine ethyl ester, 5mM reduced glutathione, 0.1 mM oxidized glutathione. This buffer was prepared from N<sub>2</sub>-saturated water and the dialysis was performed in a capped Wheaton bottle. After 16-48 hours, dialysis bags were transferred to 4° phosphate buffered saline containing 1mM PMSF and dialysis continued another 16-24 hrs. Dialysates were assayed by ELISA as described in paragraph E.2 for ability to bind CEA. The results below show the values obtained by comparison with the standard curve in x ng/ml anti-CEA. Also shown are the reconstitution efficiencies calculated from the ELISA responses, minus the background (108 ng/ml) of cells producing K chain only, and from estimates of the levels of  $\gamma$  and K chains in the reaction mixtures.

	ng/ml anti-CEA	Percent recombination
<i>E. coli</i> W3110 producing IFN- $\alpha$ A (control)	0	--
<i>E. coli</i> (M3110/pKCEAtrp207-1*).	108	--
<i>E. coli</i> (M3110/pKCEAtrp207-1*), plus $\gamma$ -SSO <sub>3</sub>	848	0.33
<i>E. coli</i> (W3110/pKCEAtrp207-1* $\Delta$ , p $\gamma$ CEAInt2)	1580	0.76
Hybridoma anti-CEA K-SSO <sub>3</sub> and $\gamma$ -SSO <sub>3</sub>	540	0.40

E.4 Preparation of Chimeric Antibody

**[0123]** Figures 11 and 12 show the construction of an expression vector for a chimeric heavy (gamma) chain which comprises the murine anti CEA variable region and human  $\gamma$ -2 constant region.

**[0124]** A DNA sequence encoding the human gamma-2 heavy chain is prepared as follows: the cDNA library obtained by standard techniques from a human multiple myeloma cell line is probed with 5' GGGCACTC-GACACAA 3' to obtain the plasmid containing the cDNA insert for human gamma-2 chain (Takahashi, *et al.*, *Cell*, 29: 671 (1982), incorporated herein by reference), and analyzed to verify its identity with the known sequence in human gamma-2 (Ellison, J., *et al.*, *Proc. Natl. Acad. Sci. (USA)*, 79: 1984 (1982) incorporated herein by reference).

**[0125]** As shown in Figure 11, two fragments are obtained from this cloned human gamma 2 plasmid (p $\gamma$ 2). The first fragment is formed by digestion with PvuII followed by digestion with Ava III, and purification of the smaller DNA fragment, which contains a portion of the constant region, using 6 percent PAGE. The second fragment is obtained by digesting the p $\gamma$ 2 with any restriction enzyme which cleaves in the 3' untranslated region of  $\gamma$ 2, as deduced from the nucleotide sequence, filling in with Klenow and dNTPs, cleaving with Ava III, and isolating the smaller fragment using 6 percent PAGE. (The choice of a two step, two fragment composition to supply the PvuII-3' untranslated fragment provides a cleaner path to product due to the proximity of the AvaIII site to the 3 terminal end thus avoiding additional restriction sites in the gene sequence matching the 3' untranslated region site.) p $\gamma$ CEA207-1\* is digested with EcoR I, treated with Klenow and dNTPs to fill in the cohesive end, and digested with Pvu II, the large vector fragment containing promoter isolated by 6 percent PAGE.

**[0126]** The location and DNA sequence surrounding the PvuII site in the mouse gamma-1 gene are identical to the location and DNA sequence surrounding the PvuII site in the human gamma-2 gene.

**[0127]** The plasmid resulting from a three way ligation of the foregoing fragments, pChim1. contains. under the influence of trp promoter, the variable and part of the constant region of murine anti-CEA gamma 1 chain. and a portion of the gamma 2 human chain. pChim1 will. in fact. express a chimeric heavy chain when transformed into *E. coli*, but one wherein the change from mouse to human does not take place at the variable to constant junction.

**[0128]** Figure 12 shows modification of pChim1 to construct pChim2 so that the resulting protein from expression will contain variable region from murine anti CEA antibody and constant region from the human  $\gamma$ -2 chain. First, a fragment is prepared from pChim1 by treating with Nco I, blunt ending with Klenow and dNTPs, cleaving with Pvu II, and isolating the large vector fragment which is almost the complete plasmid except for short segment in the constant coding region for mouse anti CEA. A second fragment is prepared from the previously described p $\gamma$ 2 by treating with Pvu II, followed by treating with any restriction enzyme which cleaves in the variable region, blunt ending with Klenow and dNTPs and isolating the short fragment which comprises the junction between variable and constant regions of this chain.

**[0129]** Ligation of the foregoing two fragments produces an intermediate plasmid which is correct except for an extraneous DNA fragment which contains a small portion of the constant region of the murine anti CEA antigen, and a small portion of the variable region of the human gamma chain. This repair can be made by excising the Xba I to Pvu II fragment and cloning into M13 phage as described by Messing *et al.*, *Nucleic Acids Res.* 9: 309 (1981), followed by *in vitro* site directed deletion mutagenesis as described by Adelman, *et al.*, *DNA* 2, 183 (1983) which is incorporated herein by reference. The Xba I-Pvu II fragment thus modified is ligated back into the intermediate plasmid to form pChim2. This plasmid then is capable of expressing in a suitable host a cleanly constructed murine variable human constant chimeric heavy chain.

**[0130]** In an analogous fashion, but using mRNA templates for cDNA construction for human kappa rather than  $\gamma$  chain, the expression plasmid for chimeric light chain is prepared.

**[0131]** The foregoing two plasmids are then double transformed into *E. coli* W3110, the cells grown and the chains reconstituted as set forth in paragraph E.1-E.3 supra.

E.5 Preparation of FabE.5-1 Construction of a Plasmid Vector for Direct Expression of Murine Anti-CEA Gamma 1 Fab Fragment Gene p $\gamma$ CEAFabtrp207-1\*

**[0132]** Figure 13 presents the construction of p $\gamma$ CEAFabtrp207-1\*. 5  $\mu$ g of pBR322 was digested with Hind III, the cohesive ends made flush by treating with Klenow and dNTPs; digested with Pst I, and treated with BAP. The large vector fragment, fragment I, was recovered using 6 percent PAGE followed by electroelution.

**[0133]** 5  $\mu$ g of p $\gamma$ CEAtrp207-1\* was digested with both BamH I and Pst I and the ~1570 bp DNA fragment (fragment II) containing the trp promoter and the gene sequence encoding the variable region continuing into constant region and further into the anti-CEA gamma 1 chain hinge region, was isolated and purified after electrophoresis.

**[0134]** Expression of the anti-CEA gamma 1 chain Fab fragment rather than complete heavy chain requires that a



termination codon be constructed at the appropriate location in the gene. For this, the 260 bp Nco I-Nde I DNA fragment from 20 µg of the py298 was isolated and purified. A 13 nucleotide DNA primer, the complement of which encodes the last 3 C-terminal amino acids of the Fab gene and 2 bases of the 3 needed for the stop codon, was synthesized by the phosphotriester method (supra). The probe hybridizes to nucleotides 754 to 767 (Figure 4) which has the following sequence:

AspCysGlyStop

5' GGGATTGTGGTTG 3'

**[0135]** The third base of the stop codon is provided by the terminal nucleotide of the filled-in Hind III site from pBR322 cleavage described above. 500 ng of this primer was used in a primer repair reaction by phosphorylation at the 5' end in a reaction with 10 units T4 DNA kinase containing 0.5 mM ATP in 20 µl, and mixing with ~200 ng of the Nco I-Nde I DNA fragment. The mixture was heat denatured for 3 minutes at 95° and quenched in dry-ice ethanol. The denatured DNA solution was made 60mM NaCl, 7mM MgCl<sub>2</sub>, 7 mM Tris HCl (pH 7.4), 12 mM in each dNTP and 12 units DNA Polymerase I-Large Fragment was added. After 2 hours incubation at 37°C, this primer repair reaction was phenol, CHCl<sub>3</sub> extracted, ethanol precipitated, digested with BamH I and the reaction electrophoresed through a 6 percent polyacrylamide gel. ~50 ng of the 181 bp blunt end to BamH I DNA fragment, fragment III, was isolated and purified.

**[0136]** ~100 ng of fragment I, ~100 ng each of fragments II and III were ligated overnight and transformed into E. coli K12 strain 294. Plasmid DNA from several tetracycline resistant transformants was analyzed for the proper construction and the nucleotide sequence through the repair blunt end filled-in Hind III junction was determined for verification of the TGA stop codon.

#### E.5.2 Production of Fab Protein

**[0137]** The plasmid prepared in E.5.1 is transformed into an E. coli strain previously transformed with pKCEAtrp207-1\* as described above. The cells are grown, extracted for recombinant antibody chains and the Fab protein reconstituted as described in E.1.10.

#### Claims

1. A non-glycosylated chimeric immunoglobulin species having specificity for a particular known antigen comprising chimeric heavy and light polypeptide chains each having a constant region from a human antibody and a variable region from a murine antibody.

#### Patentansprüche

1. Nichtglykosylierte, chimäre Immunglobulin-Spezies, die Spezifität für ein bestimmtes bekanntes Antigen aufweist, das chimäre schwere und leichte Polypeptidketten umfasst, die jeweils eine konstante Region von einem Human-Antikörper und eine variable Region von einem Mäuse-Antikörper aufweisen.

#### Revendications

1. Espèce d'immunoglobuline chimérique non glycosylée ayant une spécificité pour un antigène connu particulier comprenant des chaînes polypeptidiques lourde et légère chimériques, chacune ayant une région constante d'un anticorps humain et une région variable d'un anticorps de murin.




Fig. 1.

1 GTTGCTGTGG TTGCTCTGGTGTG TTGAAGGAGA CATGTGTGATG ACCCAGTCTC ACAAATTCAT GTCCACATCA GTAGGAGACA GGGTCAGCAT CACCTGCAAG haeIII  
CAACGACACC AACAGACCCAC AACCTTCCTCT GTAACACTAC TGGGTCAGAG TGYTTAAGTA CAGGTGTAGT CATCCTCTGT CCCAGTGTGTA GTGGACGTTC haeI  
tthIII hphI  
sfanI

101 GCCAGTCAGG ATGTGGGTGC TGCTATAGCC TGGTATCAAC AGAAACCCAGG ACAATCTCCT AAACACTCTGA TTTACTGGGC ATCCACCCGG CACACTGGAG hinfI  
CGGTCAGTCC TACACCCACG ACGATATCGG ACCATAGTTG TCTTTGGTCC TGTTAGAGGA TTTGATGACT AAATGACCCG TAGGTGGGCC GTGTGACCTC  
fokI sfanI

201 TCCCTGATCG CTTACACAGG AGTGGATCTG GGACAGATTT CACCTCTCACC ATTAGCAATG TGCAGTCTGA TGACTTGGCA GATTATTTCT hincII  
AGGGACTAGC GAAGTGTCCG TCACCCTAGAC CCTGTCTAAA GTGAGAGTGG TAATCGTTAC ACGTCAGACT ACTGAACCGT CTAATAAAGA CAGTTGTTAT

301 TAGCGGGTAT CCTCTCAGT YCGGTGCTGG GACCAAGCTG GAGCTGAAC GGGCTGATGC TGCACCAACT GTATCCATCT TCCCACCATC CAGTGAGCAG hpaI  
ATCGCCCATG GGAGAGTGCA AGCCACGACC CTGGTTCGAC CTCGACTTG CCGACTAG ACGTGGTTGA CATAGGTAGA AGGGTGGTAG GTCACTCGTC hincII  
sau96 fnu4HI  
mnlI mboI  
bbs

401 TTAACATCTG GAGGTGCCCTC AGTCGTGTGC TTCTTGAACA ACTTCTACCC CAAAGACATC AATGTCAAGT GGAAGATTGA TGGCAGTGAA CGACAAAATG acyI  
AATTGTAGAC CTCCACGGAG TCAGCACACG AAGAAGCTGT TGAAGATGG GTTCTGTAG TTACAGTTCA CCTTCTAAT ACCGTCACCT GCTGTTTTAC  
mnlI ddeI  
mboI

Fig.2A.

```

501      hgaI      sau3A      fnu4HI      mnlI      hincII      aluI
      GCGTCCCTGAA CAGTGGACT GATCAGGACA GCAAAGACAG CACCTACAGC ATGAGCAGCA CCCTCACGTT GACCAAGGAC GAGTATGAAC GACATAACAG
      CGCAGGACTT GTCAACCTGA CTAGTCCCTGT CGTTTCTGTC GTGGATGTCG TACTCGTCTGT GGGAGTGCAA CTGGTTCCTG CTCATACTTG CTGTATTGTC

601      mnlI      haeIII      haeI      hphI      aluI      sau96      hgaI      ddel      avall      acyl
      CTATACCTGT GAGGCCACATC ACAAGACATC AACTTCACCC ATTGTCAAGA GCTTCAACAG GAATGAGTGT TAGAGACAAA GGTCCCTGAGA CGCCACCACC
      GATATGGACA CTCGGGTGAG TGTCTGTAG TTGAAGTGGG TAACAGTCTT CGAAGTTGTC CTTACTCACA ATCTCTGTTT CCAGGACTCT GCGGTGGTGG

701      aluI      aluI      mboll      ddel      mnlI      hgaI      mnlI      mnlI      mnlI
      AGCTCCCCAG CTCCATCCCTA TCTTCCCTTC TAAGGTCTTG GAGGCTTCCC CACAAGCGAC CTACCACCTGT TSCGGTGCTC CAAACCTCCT CCCCACCTCC
      TCGAGGGGTC GAGGTAGGAT AGAAGGGGAG ATTCCAGAAC CTCGGAAGGG GTGTTCGCTG GATGGTGACA ACGCCACGAG GTTTGGAGGA GGGGTGGAGG
      foki

801      mnlI      mnlI      mnlI      xmnlI      hinfI
      TTCCTCTCTT CCTCCCTTTC CTGGCTTTT ATCATGTCTAA TATTIGCAGA AAATATTCAA TAAAGTGAGT CTTTGCACCT GA
      AAGAGGAGGA GGAGGGAAG GAACCGAAA TAGTACGAT ATAAACGCT TTTATAAGT ATTTCACCTCA GAAACGTGAA CT

nucleotides: 882
```

Fig. 2B.



[illegible]

Fig. 3.

```

1      hinfI      sau96      ddel      aluI      sfaNI
      GAGTCAGCAC TGAACACGGG CCCCTCACGA TGAACCTTCGG GCTCAGCTTG ATTTACCTTG TCCTTGTTTT AAAAGTTGTC CAGTGTGAAG TGATGCTGGT
      CTCAGTCGTG ACTTGTGCCT GGGGAGTGCT ACTTGAAGCC CGAGTCGAAC TAAATGGAAC AGGAACAAA TTTTCAACAG GTCACACTTC ACTACGACCA

101     scrFI      sau96      fnu4HI      bby mnlI      hinfI
      GGAGTCTGGG GGAGTCTTAA TGGAGCCTGG AGGCTCCCTG AAACCTCTCCT GTGCAGCCTC TGGATTCACT TTCAGTAGAT ATGCCATGTC TTGGGTTCCG
      CCTCAGACCC CCTCAGAAAT ACCTCGGACC TCCGAGGGAC TTTGAGAGGA CACGTCGGAG ACCTAAGTGA AAGTCATCTA TACGGTACAG AACCCAAAGCG

201     hpaII      mnlI      hinfI      mboII      hphI
      CAGACTCCGG AGAAGAGGGCT GGAGTGGGTC GCAACCATTA GTAGTGGTGG TAGTTCACAC CTTCCATCCA GACAGTGTGA AGGGCGATTC ACCATCTCCA
      GTCTGAGGCC TCTTCTCCGA CCTCACCCAG CGTTGGTAAT CATCACCCACC ATCAAGTGTG GAAGGTAGGT CTGTCACACT TCCCGCTAAG TGGTAGAGGT

301     mnlI      mnlI      haeIII      mnlI
      GAGACAATGC CAAGAACACC CTGTACCCTGC AAATGAGCAG TCTGAGGTCT GAGGACACCG CCATGTATTA CTGTGCAAGA CCCCTCTCTTA TTTCGTTAGT
      CTCTGTTACG GTTCTTGIGG GACATGGACG TTTACTCGTC AGACTCCAGA CTCCTGTGCC GGTACATAAT GACACGTTCT GGGGGAGAAT AAAGCAATCA

401     mnlI      hphI      ddel      mnlI      xhoII
      AGCGGACTAT GCTATGGACT ACTGGGGTCA AGGAACCTCA GTCACCGTCT CCTCAGCCAA AACGACACCC CCATCTGTCT ATCCACTGGC CCTGGATCT
      TCGCCTGATA CGATACCTGA TGACCCCGAGT TCCTTGGAGT CAGTGGCAGA GGAGTCGGTT TTGCTGTGGG GGTAGACAGA TAGGTGACCG GGGACCTAGA
      scrFI      sau96      sau3A      ecorII      dpnI
```

Fig. 4A.

501 fnu4HI ncoI scrFI ffaNI foki hphI ecorII scrFI xhoII sau3A  
bbv bstEII ecorII ddel dpnI  
GCTGCCCAA CTAACCTCCAT GGTGACCCCTG GGATGCTGG TCAAGGGCTA TTTCCCTGAG CCAGTGACAG TGACCTGGAA CTCTGGATCC CTGTCCAGCG  
CGACGGGTTT GATTGAGTA CCACTGGGAC CCTACGGACC AGTTCCCGAT AAAGGGACTC GGTCACTGTC ACTGGACCTT GAGACCTAGG GACAGGTCGC

601 hgiA pvuII aluI pstI mnlI ddel aluI mnlI haeIII hphI  
GTGTGCACAC CTTCCTCAGCT GTCTGTCAGT CTGACCTCTA CACTCTGAGC AGCTCAGTGA CTGTCCCTC CAGCCCTCGG CCCAGCGGAGA CCGTCACCTG  
CACACGTGTG GAAGGGTCGA CAGGACGTCA GACTGGAGAT GTGAGACTCG TCGAGTCACT GACAGGGGAG GTCGGGAGCC GGTCTGCTCT GGCAGTGGAC

701 scrFI haeIII fnu4HI bglI hpaII bbv scrFI ecorII ndeI rsaI  
CAACGTTGCC CACCCGGGCA GCAGCACCAA GGIGGACAAG AAAATTGTGC CCAGGGATTG TGGTTGTAAG CCTTGCCATAT GTACAGTCCC AGAAGTATCA  
GTTGCAACGG GTGGGCCGGT CGTCGTGGTT CCACCTGTTT TTTTAAACAG GGTCCTTAAC ACCAACATTC GGAACGTATA CATGTCAGGG TCTTCATAGT

801 mbolI mbolI foki hgiA hphI mstII hinfI ddel accI foki sau3A  
TCTGTCTTCA TCTTCCCCCC AAAGCCCAAG GATGTGCTCA CCATTACTCT GACTCCTAAG GTACCGTGTG TTGTGGTAGA CATCAGCAAG GATGATCCCG  
AGACAGAGT AGAAGGGGGG TTTCGGGTTT CTACACGAGT GGTAAATGAGA CTGAGGATTG CAGTGACAC CAGTCTGTTT CTACTAGGGC

901 sau96 pvuII mnlI hgiA aluI hgiA ddel hpaII mnlI ddel  
avaII aluI  
AGGTCCAGTT CAGCTGGTTT GTAGATGATG TGGAGGTGCA CACAGCTCAG ACCCAACCCC GGGAGGAGCA GTTCAACAGC ACTTCCGCT CAGTCAGTGA  
TCCAGGTCAA GTCGACCAA CATCTACTAC ACCTCCACGT GTGTGAGTC TGGGTGGGG CCTCTCTCGT CAAGTTGTG TGAAGGGCGA GTCAGTCACT

Fig. 4B.

```

1001      scrFI      fnu4HI      hincII      aIuI      taqI
      ecorII      bbv      aluI
      ACTTCCCATC ATGCACCCAGG ACTGGCTCAA TGGCAAGGAG TTCAAAATGCA GGGTCAACAG TGCAGCTTTC CCTGCCCCCA TCGAGAAAC CATCTCCAA
      TGAAGGTAG TACGTGGTCC TGACCGAGT ACCGTCCCTC AAGTTACGT CCCAGTTGTC ACGTCGAAAG GGACGGGGGT AGCTCTTTTG GTAGAGGTTT

1101      rsal      haeIII      haeI      balI
      ACCAAAGGCA GACCGAAGGC TCCACAGGTG TACACCATTC CACCTCCCAA GGAGCAGATG GCCAAGGATA AAGTCAGTCT GACCTGCAATG ATACAGACT
      TGGTTTCCGT CTGGCTTCCG AGGTGTCAC ATGTGTAAG GTGGAGGGTT CCTGCTCTAC CGGTTCCTAT TTCAGTCAGA CTGGACGTAC TATTGTCIGA

1201      mboII      mboII      fnu4HI      bbv      ddeI
      TCTTCCTGA AGACATTACT GTGGAGTGGC AGTGGAAATGG GCAGCCAGCG GAGAACTACA AGAACACTCA GCCCATCATG AACACGAATG GCCTTACTT
      AGAAGGGACT TCTGTAATGA CACCTCACCG TCACCTTACC CGTCGGTCCG CTCCTGATGT TCTTGTGAGT CGGGTAGTAC TTGTGCTTAC CGAGAATGAA

1301      accI      aluI      mboII      mnlI      hphI      haeIII      sau96      mnlI      mboII
      CGTCTACAGC AAGCTCAATG TGCAGAAGAG CAACCTGGGAG GCAGGAAATA CTTCACCTG CTCGTGTGTTA CATGAGGGCC TGCACACCA CCATCTGAG
      GCAGATGTCG TTCGAGTTAC ACGTCTTCTC GTTGACCTTC GTTCCCTTAT GAAAGTGGAC GAGACACAAT GTACTCCCGG ACGTGTGGT GGTATGACTC

1401      mnlI      scrFI      sau3A      dpnI      hinfI      mnlI      mnlI
      AAGAGCCTCT CCCACTCTCC TGGTAAATGA TCCCAGTGTG CTGGAGGCC CTGTGTCCTA CAGGACTCTG ACACCTACCT CCACCCCTCC CTGTATAAT
      TTCTCGGAGA GGTGAGAGG ACCATTTACT AGGTTCACAG GAACCTCCGG AGACCCAGGAT GTCTGAGAC TGTGGATGGA GTGGGGGAGG GACATATTTA

1501      AAAGCACCCA GCACAGCCTT GGGAAAAA
      TTTCGTGGGT CGTGACGGAA CCGTTTTT

```

Fig. 4C.



GAGUCAGCACUGAACACGGACCCUCACG    met asn phe gly leu ser leu ile tyr leu val leu val leu val lys val val gln cys glu  
 AUG AAC UUC GGC CUC AGC UUG AUU UAC CUU GUC CUG GUU UUA AAA GUA GUU GUC CAG UGU GAA  
 -10  
 1  
 val met leu val glu ser gly glu pro glu pro gly gly ser leu lys leu ser cys ala ala ser gly phe thr phe ser arg  
 GUG AUG CUG GUG GAG GAG UCU GGG GGA GUC UUA AUG GAG GAG CCU GGC UCC CUG AAA CUC UCC UGU GCA GCC UCU GGA UUC ACU UUC AGU AGA  
 10  
 20  
 30  
 tyr ala met ser trp val arg gln thr pro glu lys arg leu glu trp val ala thr ile ser ser gly gly ser ser his leu pro ser  
 UAU GCC AUG UCU UGG UGU CGC CAG ACU CCG GAG AAG AGG AGG CUG CUG GAG UGG GUC GCA ACC AUU AGU AGU UCA CAC CUU CCA UCC  
 40  
 50  
 60  
 arg gln cys glu gly arg phe thr ile ser arg asp asn ala lys asn thr leu tyr leu gln met ser ser leu arg ser glu asp thr  
 AGA CAG UCU GAA GGG CGA UUC ACC AUC UCC AGA GAC AAU GCC AAG AAC ACC CUG UAC CUG CAA AUG AGC AGU CUG AGG UCU GAG GAC ACG  
 70  
 80  
 90  
 ala met tyr tyr cys ala arg pro pro leu ile ser leu val ala asp tyr ala met asp tyr trp gly gln gly thr ser val thr val  
 GCC AUG UAU UAC UGU GCA AGA CCC CCU CUU AUU UCG UUA GUA GCG GAC UAU GCU AUG GAC UAC UGG GGU CAA GGA ACC UCA GUC ACC GUC  
 100  
 110  
 120  
 ser ser ala lys thr thr pro pro pro val tyr pro leu ala pro gly ser ala ala gln thr asn ser met val thr leu gly cys leu  
 UCC UCA GCC AAA ACG ACA CCC CCA CCU UCU GUC UAU CCA CUG GCC CCU GGA UCU GCU GCC CAA ACU AAC UCC AUG GUG ACC CUG GGA UGC CUG  
 130  
 140  
 150  
 val lys gly tyr phe pro glu pro glu phe thr val thr trp asn ser gly val his thr phe pro ala val leu gln  
 GUC AAG GGC UAU UUC CCU GAG CCA GUG ACA GUG ACC UGG AAC UCU GGA UCC CUG UCC AGC AGC GGU GUG CAC ACC ACC CCA GCU GUC CUG CAG  
 160  
 170  
 180  
 ser asp leu tyr thr leu ser ser ser val thr val pro ser ser pro arg pro arg cys asn val ala his pro ala  
 UCU GAC CUC UAC ACU CUG AGC AGC UCA GUG ACU GUG ACC UCC UCC AGC CCU CGG CCC GAG ACC GUC ACC UGC AAC GUA GCC CAC CCG GCC  
 190  
 200  
 210  
 ser ser thr lys val asp lys lys ile val pro arg asp cys gly cys lys pro cys ile cys thr val pro glu val ser ser val phe  
 AGC AGC ACC AAG GUG GAC AAG AAA AUU GUG CCC AGG GAU UGU GGU UGU AAG CCU UGC AUA UGU ACA GUC CCA CCA GAA GUA UCA UCU GUC UUC  
 220  
 230  
 240

Fig. 5A.

Fig. 5B.




Fig.6.





Fig. 7.





*Fig. 8A.*






Fig. 8B.



*Fig. 8C.*



Fig. 9.

*Fig. 10.*







Fig. 11.






Fig. 13.